Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism (Q61644023)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

title

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

author name string

Wiborg O

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

language of work or name

English

0 references

publication date

1 July 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

17 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

volume

60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

page(s)

41-47

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations

17 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Dose-response relationships of perphenazine in the treatment of acute psychoses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

15 Genetic analysis of cytochrome P450 system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Debrisoquine oxidation phenotype during neuroleptic monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Substantial rise in sparteine metabolic ratio during haloperidol treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Plasma level monitoring of antipsychotic drugs. Clinical utility

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

In vitro methods for assessing human hepatic drug metabolism: their use in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0009-9236(96)90165-4

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0009-9236(96)90165-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8689810 AND SRC:MED&resulttype=core&format=json

17 October 2019

1 reference